House Bill 3520
116th Congress(2019-2020)
Stem Cell Therapeutic and Research Reauthorization Act of 2019
Introduced
Introduced in House on Jun 26, 2019
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
3520
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
No House votes have been held for this bill.
Summary
Stem Cell Therapeutic and Research Reauthorization Act of 2019
This bill modifies and reauthorizes through FY2024 the C.W. Bill Young Cell Transplantation Program, which provides support to patients who need a potentially life-saving bone marrow transplant or umbilical cord blood transplant. It also reauthorizes through FY2024 the Stem Cell Therapeutic and Research Act of 2005, which provides for the collection and maintenance of new units of high-quality cord blood.
The bill requires the Advisory Council on Blood Stem Cell Transplantation to convene at least twice per calendar year.
June 26, 2019
Sort by most recent
06/27/2019
Referred to the Subcommittee on Health.
06/26/2019
Referred to the House Committee on Energy and Commerce.
06/26/2019
Introduced in House
Public Record
Record Updated
Nov 1, 2022 1:50:52 PM